Dr Ajay Vyas, Director–Nuclear Medicine, Kailash Deepak Hospital, explains why time is the most critical variable in cancer care. In this perspective, he highlights how late-stage diagnosis not only reduces survival chances but also dramatically increases treatment complexity, healthcare costs, and pressure on hospital infrastructure
Cancer care outcomes are fundamentally timesensitive. The stage at which malignancy is diagnosed acts as the single most powerful determinant of survival, treatment complexity, infrastructure utilisation, and long-term healthcare expenditure. In high-volume oncology settings, the contrast between early-stage and advanced-stage diagnosis is not merely clinical – it represents a divergence in resource intensity, economic burden, and system-wide efficiency.
Stage migration and survival economics
India continues to experience a pronounced stage migration phenomenon, with approximately 60–70 per cent of cancers being diagnosed at Stage III or IV. This epidemiological reality drives inferior survival outcomes and exponentially increases the cost of care. Five year survival rates drop precipitously once disease extends beyond organ-confined stages, while therapeutic intensity escalates from single-modality to complex multimodal regimens.
Non-linear cost escalation in advanced disease
Healthcare expenditure in oncology follows a non-linear curve. Early-stage disease is typically managed with definitive surgery and limited adjuvant therapy. In contrast, advanced disease necessitates prolonged hospitalisation, repeated cross-sectional and functional imaging, extended radiotherapy schedules, highcost targeted therapies, immunotherapy, and intensive supportive care. Each incremental delay magnifies cumulative cost while diminishing marginal survival benefit.
Infrastructure load and capacity erosion
Late-stage cancer exerts disproportionate pressure on tertiary-care infrastructure. Advanced cases consume three to four times more inpatient beddays, significantly higher ICU utilisation, and increased dependency on nuclear medicine (especially PET-CT), interventional radiology, Radiotherapy (LINAC) and palliative care services. This creates downstream bottlenecks, reducing system throughput and crowding out early-stage, potentially curative patients.
Healthcare expenditure in oncology follows a non-linear curve.Early-stage disease is typically managed with definitive surgery and limited adjuvant therapy.In contrast,advanced disease necessitates prolonged hospitalisation,repeated cross-sectional and functional imaging, extended radiotherapy schedules,high-cost targeted therapies,immunotherapy,and intensive supportive care
Geographic inequity and referral lag
Centralisation of advanced oncology services within metropolitan hubs has historically contributed to diagnostic delay. Patients from Tier II and Tier III regions often present late due to logistical, financial, and informational barriers. This referral lag compounds disease progression and inflates indirect costs such as travel, accommodation, and loss of productivity.
Technology as a force multiplier
The integration of artificial intelligence in radiology and pathology, expansion of PETCT–guided staging, and virtual multidisciplinary tumour boards has the potential to significantly compress diagnostic timelines. Decentralisation of nuclear medicine and advanced radiotherapy platforms enables earlier intervention and reduces dependency on overburdened metropolitan centres.
Policy imperatives and economic rationality
From a health economics perspective, early detection represents the highest return-on-investment intervention in oncology. Resource allocation toward population-based screening, risk-stratified surveillance, and transparent financial counselling is far more cost-effective than downstream expenditure on latestage disease. Public–private partnerships are essential to scale these interventions across India’s diverse demographic landscape. Even the lower import taxes may help in reduce the initial cost of oncology project.
Conclusion
The battle against cancer is as much chronological as it is biological. While therapeutic innovation continues to improve outcomes even in advanced disease, the sustainability of India’s oncology ecosystem depends on systematic compression of diagnostic and treatment delays. Early detection is not merely a clinical objective; it is an infrastructural, economic, and ethical imperative.